• LLY-507 SMYD2 Inhibitor: Research Workflows

  2026-09-08

  LLY-507 enables selective interrogation of SMYD2-dependent methylation, cancer cell proliferation inhibition, and stress-response signaling. This practical guide connects biochemical target engagement with cell-based validation and the renal fibrosis findings reported in a cisplatin injury model.

• Foretinib (GSK1363089) Assay Guide

  2026-09-08

  Build more informative cancer experiments with Foretinib by separating proliferation arrest, cell death, and motility rather than relying on a single viability endpoint. This practical guide connects dose design and orthogonal readouts to Met/VEGFR biology, migration studies, and translational metastasis models.

• Pazopanib Hydrochloride: Assay Reliability

  2026-09-07

  This practical guide shows how SKU A8347, Pazopanib Hydrochloride, can support more interpretable viability, proliferation, and cytotoxicity experiments. It connects the compound’s kinase selectivity and formulation data with evidence-based strategies for separating growth inhibition from cell death.

• Sunitinib B1045: Reliable Cancer Assay Workflows

  2026-09-07

  This scenario-driven guide explains how Sunitinib (SKU B1045) can improve experimental consistency in viability, proliferation, apoptosis, and resistance studies. It connects formulation, storage, assay design, and recent renal cell carcinoma evidence to practical laboratory decisions.

• HR-LCMS/MS Reveals a New Glabrol Source

  2026-09-05

  This study presents a streamlined HR-LCMS/MS-based dereplication workflow that connects autophagy activity in plant fractions with candidate bioactive metabolites. By screening medicinal plants in SH-SY5Y cells, the authors identified Astragalus dasyanthus as a previously unrecognized producer of the autophagy-inducing compound glabrol.

• Telatinib (BAY 57-9352) Assay Guide

  2026-09-04

  A scenario-based guide to using Telatinib (BAY 57-9352), SKU A8550, in viability, proliferation, cytotoxicity, invasion, and angiogenesis workflows. It connects reported kinase potency with practical DMSO handling, dose design, phenotype interpretation, combination testing, and product-selection criteria.

• Sunitinib: A Resistance-Aware Assay Guide

  2026-09-04

  Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with applications extending from angiogenesis studies to resistance biology. This guide translates TRIB3–SLC7A11/GPX4 findings into practical assay design for renal cell carcinoma and related tumor models.

• ATRX Loss Sensitizes Glioma to RTK Inhibitors

  2026-09-03

  The reference study identifies ATRX deficiency as a potential biomarker of increased sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data with temozolomide support genotype-aware treatment evaluation, while also highlighting the need to distinguish cellular drug sensitivity from clinical efficacy.

• (S)-Mephenytoin in Organoid PK Assays

  2026-09-03

  Explore how (S)-Mephenytoin can qualify CYP2C19 activity in hiPSC-derived intestinal organoids. This article presents an assay-design framework that separates enzyme turnover from transport, maturation, and barrier effects.

• GZMK+ CD8+ T Cells Drive Recurrent Airway Inflammation

  2026-09-02

  The reference study identifies persistent GZMK-expressing CD8+ effector-memory T cell clones as a cellular basis for recurrent nasal polyps and related airway inflammation. By linking T cell clonality to GZMK-dependent complement cleavage, human tissue biomarkers, and intervention in a mouse asthma model, the work provides a mechanistic framework for studying inflammatory disease recurrence.

• MRT68921 ULK1 Kinase Inhibitor Workflow

  2026-09-02

  MRT68921 enables controlled blockade of autophagy initiation, making it useful for separating ULK-dependent effects from rapamycin-driven responses in lipid-stressed cells. This workflow connects ATG13 phosphorylation, LC3 flux measurement, lipidomics, and proteomics to practical assay decisions.

• Hydrocortisone Beyond the Bench: Designing Translation

  2026-09-01

  Hydrocortisone is more than a reference glucocorticoid hormone: it is a mechanistic probe and a translational design variable. This article connects receptor biology, inflammation and neuroprotection models, and PLGA-based corticosteroid delivery to help researchers build more predictive development strategies.

• AY 9944: From Sterol Control to Antiviral Insight

  2026-09-01

  DHCR7 is emerging as more than a cholesterol-biosynthesis enzyme. This thought-leadership guide connects AY 9944 dihydrochloride-based sterol perturbation with genetic evidence from GCRV-resistant grass carp, while outlining how translational researchers can separate validated biology from experimental opportunity.

• ATRX Loss Rewires RTK Inhibitor Sensitivity

  2026-08-31

  The reference study identifies ATRX deficiency as a potential determinant of sensitivity to multi-targeted receptor tyrosine kinase and PDGFR inhibitors in high-grade glioma cells. Its combination data further support evaluating ATRX status when studying RTK inhibitor and temozolomide treatment strategies, while highlighting the need for genotype-aware interpretation of clinical trials.

• Pazopanib Hydrochloride: In Vitro Workflow

  2026-08-31

  Build more informative Pazopanib Hydrochloride experiments by separating growth inhibition from actual cell killing. This workflow combines dose-response design, time-resolved viability measurements, and angiogenesis-relevant assays to improve interpretation in cancer research.

8404 records 5/561 page Previous Next 12345 下5页 Last page